{"entity":{"id":"nct06239155","kind":"trial","name":"A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of AST-3424 in hepatocellular carcinoma, run by Ascentawits Pharmaceuticals, Ltd, active and no longer recruiting.","summary":"A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06239155 by Ascentawits Pharmaceuticals, Ltd, with 51 participants enrolled, started 2019-09-03 and due to reach its primary completion in 2025-11-30. Interventions recorded: AST-3424.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06239155","url":"https://clinicaltrials.gov/study/NCT06239155"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ascentawits-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06239155","phase":"1/2","setting":"Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of AST-3424 in Treatment of Patients With Advanced Solid Tumors and Its Correlation With AKR1C3 Enzyme Expression","sponsor":"Ascentawits Pharmaceuticals, Ltd","enrolled":51,"outcomes":[]},"route":"/trials/nct06239155/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"company":[{"id":"ascentawits-pharmaceuticals","kind":"company","name":"Ascentawits Pharmaceuticals","route":"/companies/ascentawits-pharmaceuticals/"}]}}